Latest news

Mundipharma EDO GmbH: US FDA grants Orphan Drug Designation for tinostamustine in very rare blood cancer

28 Mar 2019

Mundipharma EDO GmbH initiates expansion phase of first-in-human trial to investigate use of tinostamustine in rare and difficult-to-treat blood cancers

5 Mar 2019

Mundipharma EDO GmbH: US FDA grants Orphan Drug Designation for etoposide toniribate in relapsed/refractory biliary tract cancer

22 Feb 2019

Mundipharma EDO attend ASH 2018

3 Dec 2018

Jason Hall joins the Mundipharma EDO team

1 Nov 2018

Mundipharma EDO expands clinical development team

15 Jul 2018

EDO announces next milestone for tinostamustine (EDO-S101) as first-in-human solid tumor study begins

9 Oct 2017

Mundipharma and CellAct announce new deal for the worldwide development and commercialization of smart chemotherapy CAP7.1

9 Aug 2017

Mundipharma EDO GmbH announces first-in-human clinical trial of its lead compound, EDO-S101

20 Jul 2016

Blog

Myeloma Action Month

25 Mar 2019

Media enquiries

For media enquiries please contact:

Tiffany Fretwell
Communications Lead at Mundipharma EDO
[email protected]
Direct:   +44 (0) 1223 393 361
Mobile:  +44 (0) 7773 199 422

Alternatively, you can also contact:

Makara Health
[email protected]
call +44 (0)23 8124 7327